American journal of clinical pathology最新文献

{"title":"Diagnostic utility of lymphocyte enhancer factor 1 in aggressive B-cell lymphoma with MYC rearrangement.","authors":"Xin Wang, Maria Faraz, Anne Chen, Tipu Nazeer, Xiaoyan Huang","doi":"10.1093/ajcp/aqae189","DOIUrl":"10.1093/ajcp/aqae189","url":null,"abstract":"<p><strong>Objectives: </strong>We sought to investigate the diagnostic value of lymphocyte enhancer factor 1 (LEF1) expression in aggressive B-cell lymphomas (BCL) with MYC gene rearrangement (MYC-R).</p><p><strong>Methods: </strong>Sixty-seven cases of BCL were studied and included Burkitt lymphoma (BL) (23 cases); diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) with MYC-R (13 cases); and DLBCL/high-grade B-cell lymphoma with MYC, BCL2, and/or BCL6 rearrangements (double-hit [DH] or triple-hit [TH], 17 cases). Random DLBCL-NOS (14 cases) without MYC-R was recruited as a control group. By immunohistochemical stains, 3 patterns of LEF1 staining were recorded as pattern 0 (negative), pattern 1 (weak and heterogeneous staining, <80%), and pattern 2 (moderate/strong and uniform staining, ≥80%).</p><p><strong>Results: </strong>Pattern 1 can be seen in all BCLs with MYC-R included in this study and more commonly seen in DLBCL without MYC-R (8/14 cases). Pattern 2 is characteristic (positive predictive value = 86%) for Epstein-Barr virus (EBV)-negative BL, while pattern 0 was seen in 22 (76%) of 29 cases of DLBCL-MYC-R/DH/TH (P < .001). Seven of 8 EBV-positive BL cases showed pattern 0, which was completely opposite to the common pattern 2 in EBV-negative BL (12/15 cases). Pattern 2 was not detected in all DH/TH cases.</p><p><strong>Conclusions: </strong>Weak and heterogeneous staining of LEF1 can be seen in all the BCLs with and without MYC-R. Strong and uniform staining of LEF1 is highly characteristic of EBV-negative BL among all aggressive BCLs with MYC-R, while the negative staining of LEF1 is mostly suggestive of DLBCL-MYC-R/DH/TH. Lymphocyte enhancer factor 1 provides additional diagnostic value in the differentiation of BL from other aggressive BCLs with MYC-R, especially in a limited specimen.</p>","PeriodicalId":7506,"journal":{"name":"American journal of clinical pathology","volume":" ","pages":"815-821"},"PeriodicalIF":2.3,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143254141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Primary low-grade salivary gland-type intraductal carcinoma of the lung with CCDC6::RET fusion: Case presentation and literature review.","authors":"Bei Wang, Xiaowei Wang, Ziyi Chang, Dingrong Zhong","doi":"10.1093/ajcp/aqaf014","DOIUrl":"10.1093/ajcp/aqaf014","url":null,"abstract":"<p><strong>Objectives: </strong>Salivary gland-type intraductal carcinoma (IC) is a rare type of low-grade salivary gland neoplasm. Given that the clinical and imaging features of primary lung IC are nonspecific, the diagnosis requires pathologic analysis.</p><p><strong>Methods: </strong>We report a 63-year-old woman with primary low-grade salivary gland-type IC of the lung, characterized by an origin from the bronchus submucosa, an intraductal or intracavity growth of ductal epithelium, an absence of interstitial infiltration, and harboring an RET::CCDC6 fusion.</p><p><strong>Results: </strong>Through case presentation and a literature review, we discuss the differential diagnosis and clinical management of salivary gland-type IC of the lung.</p><p><strong>Conclusions: </strong>Molecular testing is not necessary for histologic subtyping but can aid in the differential diagnosis of IC.</p>","PeriodicalId":7506,"journal":{"name":"American journal of clinical pathology","volume":" ","pages":"877-882"},"PeriodicalIF":2.3,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143555534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ASCP explores the cancer biomarker testing navigator as a novel role to improve laboratory operations and workflows: A special report from the ASCP Biomarker Testing Navigator Project Team.","authors":"Lynnette Pineault, Karla Valencia, Jennifer Buhay, Alexandra Brown, Suzanne Ziemnik, Melissa Kelly, James Morgante, Ananya Datta Mitra, Lindsay Yanamura, Marie Gilliland, Amy Ferea, Joseph Kim","doi":"10.1093/ajcp/aqaf028","DOIUrl":"10.1093/ajcp/aqaf028","url":null,"abstract":"<p><strong>Objective: </strong>Cancer biomarker testing is a critical element in precision oncology, guiding treatment decisions and improving patient outcomes. However, the complexity and variability of biomarker testing processes present significant challenges for cancer centers, often leading to delays and inefficiencies that can compromise care quality. The American Society for Clinical Pathology explored the concept of a novel laboratory professional role: the cancer biomarker testing navigator (BTN).</p><p><strong>Methods: </strong>This study explored the feasibility and impact of the BTN role on laboratory operations and workflows through a 3-phase project consisting of a quantitative needs assessment, qualitative focus group discussions, and a short-term feasibility pilot conducted at 2 cancer centers.</p><p><strong>Results: </strong>The needs assessment revealed that many laboratories lack dedicated staff for coordinating biomarker testing, leading to operational inefficiencies. The roundtable discussions highlighted common challenges in biomarker testing and identified potential benefits of the BTN role, such as improved communication, better tracking of send-out tests, and enhanced task efficiency. The feasibility pilot demonstrated that BTNs could coordinate multigene next-generation sequencing panels and expedite key steps to ensure optimal preanalytical processes, reduce delays in testing, and smooth operations. The BTN role represents a feasible and beneficial addition to pathology laboratories that addresses key operational challenges in cancer biomarker testing and offers a promising solution to streamline laboratory operations, improve multidisciplinary communication, and enhance patient care coordination.</p><p><strong>Conclusions: </strong>Further exploration is warranted to refine the BTN role and assess its long-term sustainability in and impact on diverse laboratory settings.</p>","PeriodicalId":7506,"journal":{"name":"American journal of clinical pathology","volume":" ","pages":"926-935"},"PeriodicalIF":2.3,"publicationDate":"2025-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12159526/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143960937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimizing electronic health records: Integration of human factors engineering for enhanced pathology report display and accessibility.","authors":"Ethan P Larsen, Mohammad Jalloul, Moira P Larsen","doi":"10.1093/ajcp/aqaf024","DOIUrl":"https://doi.org/10.1093/ajcp/aqaf024","url":null,"abstract":"<p><strong>Objective: </strong>The integration of human factors engineering (HFE) into electronic health records (EHRs) is essential to enhance the display and accessibility of pathology reports. Pathology testing is central to clinical decision-making, yet the current EHR interfaces present challenges in test ordering and result interpretation, contributing to diagnostic errors. This study explores the application of HFE principles to redesign EHR visual displays, specifically for HIV and urine toxicology testing.</p><p><strong>Methods: </strong>By involving pathologists and clinicians in the design process, we developed user-centric templates that improve result clarity and accessibility. We also describe case examples of one successful template prototype implementation and one where technical barriers highlight limitations of applying user-centered design within the constraints of EHR and Laboratory Information System applications. The redesigned reports emphasize critical information through standardized color codes and organized data presentation, making nonstandard findings more prominent.</p><p><strong>Discussion: </strong>These interventions have the potential to create improved clinician comprehension and workflow efficiency, ultimately supporting better patient care. The study highlights the importance of incorporating HFE principles into EHR design and advocates for broader adoption to enhance usability and safety in health care settings.</p><p><strong>Conclusions: </strong>Further collaboration with regulatory bodies could establish standardized guidelines, fostering more effective EHR systems across the industry.</p>","PeriodicalId":7506,"journal":{"name":"American journal of clinical pathology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144172360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"KRAS may facilitate transformation of chronic lymphocytic leukemia to histiocytic sarcoma with indeterminate dendritic cell features.","authors":"Farhan Hassan, Hailing Zhang, Dietrich Werner Idiaquez, Nagehan Pakasticali, Elizabeth Hyjek, Mohammad Hussaini","doi":"10.1093/ajcp/aqaf041","DOIUrl":"https://doi.org/10.1093/ajcp/aqaf041","url":null,"abstract":"<p><strong>Objective: </strong>We sought to investigate the molecular mechanism underlying transformation of chronic lymphocytic leukemia (CLL) to histiocytic sarcoma (HS) with indeterminate dendritic cell (IDC) features.</p><p><strong>Methods: </strong>Extensive NGS-based genomic profiling was performed on samples of a patient who had CLL, secondary HS with IDC features, and CMML. Clonotypic evaluation of VDJ rearrangement status was performed to confirm clonal relatedness.</p><p><strong>Results: </strong>HS is a rare proliferation of malignant tissue histiocytes that is usually primary, although secondary HS exists and often demonstrates mutations in the Ras/Raf/MAPK or PI3K/AKT/mTOR pathways, but HS with indeterminate dendritic cell (IDC) features has not been previously reported. A 77-year-old man with chronic lymphocytic leukemia (CLL) presented with an oropharyngeal mass. Biopsy specimen showed large atypical histiocytic cells with oval-to-irregular indented nuclei. They were positive for CD33, CD4, CD68 (subset, weak), CD163 (subset, weak), BCL6, S100 (subset), CD1a, cyclin D1 (subset), and lysozyme (weak) but negative for Langerin, BRAF V600E, CD21, CD23, CD35, CD123, TCF4, TCL1, MPO, CD20, CD79a, CD10, MUM1, and BCL2. The patient was diagnosed with secondary HS with IDC features as well as chronic myelomonocytic leukemia (CMML) in the bone marrow. Careful genomic dissection of all 3 types of malignant cells showed that SF3B1 p.E622D was present in both CLL and HS but not CMML. In addition, the HS acquired KRAS p.G13D, which we hypothesize drove the transdifferentiation of CLL to HS. Moreover, next-generation sequencing (NGS) clonotypic evaluation of variable-diversity-joining (VDJ) rearrangements in both the HS and CLL established relatedness but not the CMML.Conclusion: This is the first report of secondary HS with IDC features arising from CLL. We establish by both IGH NGS analysis and mutational profiling that the CLL and HS are clonally-related and posit that acquisition of KRAS p.G13D drove transdifferentiation. This has therapeutic implications for targeting the RAS-BRAF-MAPK-ERK pathway.</p>","PeriodicalId":7506,"journal":{"name":"American journal of clinical pathology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144148762","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinicopathologic characteristics of lymphoproliferative disorders involving the kidney.","authors":"Kotaro Takeda, Haiming Tang, Deepika Kumar, Adebowale J Adeniran, Guoping Cai","doi":"10.1093/ajcp/aqaf023","DOIUrl":"https://doi.org/10.1093/ajcp/aqaf023","url":null,"abstract":"<p><strong>Objective: </strong>Lymphoproliferative disorders can involve the kidney, which is associated with a worse prognosis. The objective of this study was to review the clinical and histologic characteristics of patients with lymphoproliferative disorders involving the kidneys.</p><p><strong>Methods: </strong>Cases with lymphoproliferative disorders showing renal involvement were retrieved from the institutional pathology database for the past 20 years. Data regarding patient demographics, clinical presentations, lymphoma subtypes, history of lymphoma, treatments received, chemotherapy regimens, and patient outcomes were extracted.</p><p><strong>Results: </strong>The cohort included 48 cases of non-Hodgkin lymphoma with renal involvement, comprising 35 men and 13 women, with a median age of 71.5 years. Most lymphomas were mature B-cell neoplasms, accounting for 42 (87.5%) cases, with diffuse large B-cell lymphoma as the leading subtype in 18 (42.9%) cases. A renal mass was the initial presentation in 33 (68.8%) patients, while the remaining 15 (31.2%) had medical renal complications. Approximately half of the renal mass cases were de novo aggressive lymphomas, while most with renal complications had systemic involvement of previously diagnosed low-grade lymphomas. Chemotherapy, frequently R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone), was the primary treatment. Patients with a kidney mass tended to show a worse prognosis than those with medical renal complications, but statistical significance was not reached (P = .347).</p><p><strong>Conclusions: </strong>The study demonstrates that renal mass is a crucial presentation of lymphoma, in some cases even without history, highlighting the importance of renal biopsy to triage patients for proper treatment and avoid unnecessary nephrectomy.</p>","PeriodicalId":7506,"journal":{"name":"American journal of clinical pathology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144148761","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rapid clinical deployment of UBA1 testing in patients with VEXAS syndrome.","authors":"Paul A Wadsworth, Simon B Chen, Lauren Lawrence, Chandler C Ho, Joseph E Le, Paolo Libiran, Peter C Grayson, Marcela A Ferrada, David B Beck, Carlos J Suarez","doi":"10.1093/ajcp/aqaf051","DOIUrl":"https://doi.org/10.1093/ajcp/aqaf051","url":null,"abstract":"<p><strong>Objective: </strong>VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) is a recently described autoinflammatory syndrome caused by pathogenic variants in UBA1. However, there is a dearth of widely available UBA1 testing aside from large, expensive sequencing studies. Thus, we sought to rapidly develop, validate, and clinically deploy a cost-effective assay for detecting the most common UBA1 variants.</p><p><strong>Methods: </strong>We developed, validated, and implemented a single base extension mass spectrometry assay for detecting pathogenic UBA1 variants at the c.121, c.122, and c.118-1 positions in patients with suspected VEXAS syndrome. Assay performance characteristics were assessed using peripheral blood and bone marrow samples from patients with (n = 8) and without (n = 36) VEXAS.</p><p><strong>Results: </strong>The assay demonstrated a lower limit of detection (LOD) of 10% variant allele fraction for each mutation. The analytical accuracy, sensitivity, and specificity were each demonstrated to be 100% at the LOD, with excellent intra- and interrun reproducibility. Based on literature review of reported UBA1 variants associated with VEXAS, to date, this assay detects the most prevalent variants, with a clinical sensitivity of 97% or more.</p><p><strong>Conclusions: </strong>A cost-effective, mass spectrometry-based assay with high analytical and clinical performance can feasibly be implemented in hospital laboratories for diagnosis of VEXAS syndrome.</p>","PeriodicalId":7506,"journal":{"name":"American journal of clinical pathology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144148841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CD4 antigen loss in bronchoalveolar lavage fluid with neutrophilia and infectious organisms: A diagnostic pitfall when analyzing T-cell subsets by flow cytometry.","authors":"Lianqun Qiu, Jason E Love, William Simonson, Jonathan R Fromm, Sindhu Cherian","doi":"10.1093/ajcp/aqaf048","DOIUrl":"https://doi.org/10.1093/ajcp/aqaf048","url":null,"abstract":"<p><strong>Objective: </strong>Flow cytometric T-cell subtyping is an important component of bronchoalveolar lavage (BAL) analysis with diagnostic value in routine practice.</p><p><strong>Methods: </strong>BAL fluid was collected for differential and standard 4-color panel T-cell subtype analysis using flow cytometry, followed by a 10-color comprehensive T-cell panel to confirm CD4 T-cell antigen loss.</p><p><strong>Results: </strong>Here, we report 4 BAL cases that were incidentally identified during our daily practice over the past 5 years and showed apparent loss of detectable surface CD4 on CD3+ T cells by 2 different anti-CD4 clones. Each of these BAL fluids was rich in neutrophils and had infectious microorganisms identified on microbiological examination, including Pseudomonas aeruginosa, Haemophilus influenzae, and Mycobacterium avium complex. The dual CD4- and CD8-negative CD3+ T cells were confirmed to express α/β but not γ/δ T-cell receptor in 1 case.</p><p><strong>Conclusions: </strong>CD4 antigen loss on CD3+ T cells may be seen in neutrophil-predominant BAL fluid specimens that contain infectious microorganisms. The underlying mechanism for CD4 antigen loss is unclear but may involve proteolytic cleavage by protease and/or elastase of either neutrophilic or microbial origin, or possibly chronic antigenic stimulation. Awareness of this diagnostic pitfall is important in clinical practice to avoid misinterpretation of a falsely low CD4/CD8 ratio or a population of T cells lacking expression of CD4 and CD8 in BAL samples.</p>","PeriodicalId":7506,"journal":{"name":"American journal of clinical pathology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144148760","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Detection of TP53 mutations by immunohistochemistry in acute myeloid leukemia varies with interpreter expertise and mutation status.","authors":"Lee P Richman, Brianna F Waller, Scott B Lovitch, Ashwini Jambhekar","doi":"10.1093/ajcp/aqaf047","DOIUrl":"https://doi.org/10.1093/ajcp/aqaf047","url":null,"abstract":"<p><strong>Objective: </strong>TP53 mutations, including missense and inactivating (frameshift, splice site, and nonsense) mutations, occur in approximately 10% of myeloid neoplasms and confer adverse outcomes. Classification of myeloid neoplasms by World Health Organization and International Consensus Classification standards recognizes the importance of early detection of TP53 mutations. p53 immunohistochemistry (IHC) is a widely accessible method used to detect mutations; however, previous studies have demonstrated variable accuracy, especially for inactivating TP53 mutations. Recently, sequencing using targeted panels has seen increased use. Although highly accurate, sequencing is resource intensive and not universally available.</p><p><strong>Methods: </strong>Using 134 bone marrow samples from patients with acute myeloid leukemia evaluated for TP53 mutation by sequencing, we assessed the concordance of p53 IHC with sequencing as well as the interrater-reliability for IHC intensity and percent positivity.</p><p><strong>Results: </strong>Consistent with previous studies, we found that p53 IHC was strongly specific and modestly sensitive for missense mutations and that overall performance improved with dedicated hematopathology training. We also found that IHC performed poorly for inactivating mutations and was even variable between cases harboring identical amino acid changes. Low predicted transcriptional activity of p53 missense proteins correlated with a mutant pattern of IHC staining. The status of the second allele and variant allele frequency also affected the accuracy of p53 IHC as a surrogate for TP53 allele status.</p><p><strong>Conclusion: </strong>Cases of acute myeloid leukemia with TP53 mutations predicted to have low transcriptional activity showed reduced overall survival. Our results demonstrate limited practical utility of p53 IHC for accurate evaluation of TP53 mutation status because of multifactorial confounders.</p>","PeriodicalId":7506,"journal":{"name":"American journal of clinical pathology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144141296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A critical analysis of CellaVision systems in the modern hematology laboratory.","authors":"Brydon Panozzo, Jaineel Ramnarain, Song Chen, Hiu Lam Agnes Yuen, Maciej Tatarczuch, Shahla Vilcassim, Christopher Chang-Yew Leow, Chris Barnes","doi":"10.1093/ajcp/aqaf045","DOIUrl":"https://doi.org/10.1093/ajcp/aqaf045","url":null,"abstract":"<p><strong>Objective: </strong>This review aims to provide a comprehensive analysis of the current literature regarding the use of CellaVision digital morphology systems and to assess the emerging applications, their potential to supplement current diagnostic pathways, and-importantly-appreciate their practical and perceived limitations.</p><p><strong>Methods: </strong>A manual literature review was conducted to identify relevant journal articles and published abstracts as they relate to the application of CellaVision systems to hematology laboratory practice in human patients.</p><p><strong>Results: </strong>CellaVision systems can characterize cellular morphology with overall a high degree of accuracy-in particular, for neutrophils; lymphocytes; and common red blood cell changes, including target cells. Challenges remain, however, with the detection of particular important findings, including immature granulocytes and red blood cell agglutination. The application of CellaVision systems to emerging areas such as telepathology and parasitology are evolving, with an increasing volume of literature highlighting the technology's utility.</p><p><strong>Conclusion: </strong>CellaVision systems and associated digital technologies are poised to play an increasingly important role in hematology laboratories, with promises of enhanced accuracy and improved workflows. Several critical deficiencies highlight the necessity for continued research to support their transition into routine clinical practice.</p>","PeriodicalId":7506,"journal":{"name":"American journal of clinical pathology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144141293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}